Arialys Therapeutics Advances ART5803 Development with Initial Phase 2 Patient Treatment and FDA IND Clearance

Arialys Therapeutics Advances ART5803 Development With Phase 2 Progress and FDA Clearance for New Clinical Study in Anti-NMDA Receptor Encephalitis Arialys Therapeutics, a clinical-stage biotechnology company focused on developing precision…

Read MoreArialys Therapeutics Advances ART5803 Development with Initial Phase 2 Patient Treatment and FDA IND Clearance